Overview
Take advantage of this opportunity to network with high level colleagues and the instructor, Stephen M. Stahl, MD, PhD, author of Stahl’s Essential Psychopharmacology, third edition. In this 3-part course, participants will gain a better understanding of 7 major neurotransmitter systems, 7 major drug classes, and 10 critical concepts of psychopharmacology, including review of dozens of specific psychopharmacologic agents.
This course will also help participants develop new strategies for treatment resistance across psychopharmacology by becoming more familiar with older drugs as well as new drug combinations for difficult patients. The theoretical presentations will be adapted in case-based workshops that include treatments and outcomes of patients from Dr. Stahl’s own practice.
In addition to the 3 days of workshops, the purchase of each semester includes your choice of one of the following options:
Option 1
- One credit for a free attempt at the Master Psychopharmacology Program final exam (a $249 value!)
- A copy of Stahl’s Essential Psychopharmacology, third edition (an $85 value!)
- A copy of Stahl’s Essential Psychopharmacology: The Prescriber’s Guide, third edition (a $65 value!)
- One-year subscription to Cambridge University Press’s Stahl’s Essential Psychopharmacology Online (a $195 value!)
- Features online and searchable access to the Essential Psychopharmacology series (www.stahlonline.org)
- Two books from Stahl’s Illustrated pocketbook series (a $80 value)
Option 2
- One year NEI Membership extension (a $199 value)
Option 3
- A $125 discount coupon for any future live activity
Learning Objectives
After completing this activity, participants should be better able to fulfill the following learning objectives:
Semester One: Psychosis and Antipsychotics
- Link malfunctioning and inefficient information processing in critical brain circuits to symptoms of schizophrenia and mania
- Incorporate older medications into treatment regimens when appropriate
- Apply new strategies for patients with difficult-to-treat and treatment-resistant schizophrenia and mood disorders
- Implement antipsychotic treatment selection and dosing strategies that are designed to maximize patient adherence
|
Semester Two: Mood, Pain, Antidepressants and Mood Stabilizers
- Link malfunctioning and inefficient information processing in critical brain circuits to symptoms of mood and pain disorders
- Identify potential new mechanisms of antidepressant action
- Incorporate older medications into treatment regimens when appropriate
- Apply new strategies for patients with difficult-to-treat and treatment-resistant mood and pain disorders
- Implement individualized treatment strategies for patients with mood and pain disorders
|
Semester Three: Special Topics--Anxiety, Drug Abuse, Sleep/Wake, ADHD and Dementia
- Link malfunctioning and inefficient information processing in critical brain circuits to symptoms of psychiatric illnesses
- Apply new strategies for patients with difficult-to-treat and treatment-resistant anxiety disorders
- Implement individualized treatment strategies for patients with anxiety disorders
- Provide support and treatment options to individuals with drug abuse/dependence and psychiatric comorbidities
- Identify and manage sleep/wake disorders in psychiatric patients
- Recognize and manage the evolution of ADHD symptoms
- Recognize symptoms of early-stage dementia and implement appropriate treatment
|
Target Audience
This activity has been developed for MDs specializing in psychiatry. There are no prerequisites for this activity. Physicians in all specialties who are interested in psychopharmacology, as well as nurses, psychologists, and pharmacists, are welcome for advanced study.
Faculty
Stephen M. Stahl, MD, PhD
Over the past 12 months (January 2008 – February 2009) Dr. Stahl has served as a Consultant to Arena, Azur, Bionevia, BristolMyers Squibb, Cenerex, Eli Lilly, Endo, Forest, Janssen, Jazz, J & J, Labopharm, Lundbeck, Marinus, Neuronetics, Novartis, Noven, PamLabs, Pfizer, Pierre Fabre, Sanofi, Sepracor, Servier, Shire, SK Corporation, Solvay, Somaxon, Tetragenex and Vanda; he has served on speakers bureaus for Wyeth and Pfizer and has received grant support from Forest, J & J, Novartis, Organon, PamLabs, Pfizer, Sepracor, Shire, Takeda, Vanda and Wyeth.
|
|